Endonovo Therapeutics Inc
General ticker "ENDV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $262.8K
Endonovo Therapeutics Inc does not follow the US Stock Market performance with the rate: -43.6%.
Estimated limits based on current volatility of 21.8%: low 0.00$, high 0.00$
Factors to consider:
- Current price 88.5% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.00$, 0.02$]
- 2024-12-30 to 2025-12-30 estimated range: [0.00$, 0.02$]
Financial Metrics affecting the ENDV estimates:
- Negative: Non-GAAP EPS, $ of -0.01 <= 0.10
- Negative: Operating profit margin, % of -95.42 <= 1.03
- Positive: Return on assets ratio (scaled to [-100,100]) of 91.54 > 7.10
- Positive: 2.35 < Operating cash flow per share per price, % of 4.58
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ENDV quotes
Long-term ENDV plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.07MM | $0.14MM | $0.14MM |
Operating Expenses | $2.30MM | $3.40MM | $3.06MM |
Operating Income | $-2.23MM | $-3.26MM | $-2.92MM |
Non-Operating Income | $-0.88MM | $-15.21MM | $9.84MM |
Interest Expense | $0.94MM | $1.32MM | $1.28MM |
Income(Loss) | $-3.10MM | $-18.47MM | $6.92MM |
Profit(Loss) | $-3.10MM | $-18.47MM | $6.92MM |
Stockholders Equity | $-15.77MM | $-32.18MM | $-24.11MM |
Assets | $2.01MM | $1.28MM | $0.64MM |
Operating Cash Flow | $-0.99MM | $-0.68MM | $0.12MM |
Financing Cash Flow | $1.06MM | $0.59MM | $-0.12MM |
Earnings Per Share* | $-0.07 | $-0.23 | $0.03 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.